The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.

@article{Miknyoczki2007TheSP,
  title={The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.},
  author={Sheila J Miknyoczki and Hong Chang and Jennifer V Grobelny and Sonya Pritchard and Candace S Worrell and Natalie McGann and Mark A. Ator and Jean Husten and James Deibold and Robert L. Hudkins and Allison L Zulli and Ralph E. Parchment and Bruce A. Ruggeri},
  journal={Molecular cancer therapeutics},
  year={2007},
  volume={6 8},
  pages={2290-302}
}
The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma (RG2), rhabdomyosarcoma (RH18), neuroblastoma (NB1691), and colon carcinoma (HT29) tumor cells to temozolomide- and camptothecin-induced cytotoxicity, DNA damage, and G(2)-M arrest and on the potentiation of chemotherapy-induced myelotoxicity was evaluated using in vitro assays. In addition, the effect of the prodrug CEP… CONTINUE READING